Lupin gains on US regulatory approval for drug

Shares in Lupin Ltd gained 1.6 per cent today after U.S. Food and Drug Administration gave a tentative approval for generic version of cholesterol drug niacin, a form of vitamin B, on Monday.

Analysts tracking the sector said niacin's US sales are $1.2 billion, out of which Lupin can make $30 million in sales annually.

Copyright: Thomson Reuters 2014